Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer
© Author 2015
Received: 20 August 2014
Accepted: 6 November 2014
Published: 16 June 2015
Toxic epidermal necrolysis (TEN) is a rare acute life-threatening mucocutaneous disorder that is mostly drug-related (80%–95%). It is clinically characterized as a widespread sloughing of the skin and mucosa. AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). Gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has already been recommended as a first-line treatment in EGFR-mutant metastatic NSCLC. We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42-year-old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. On the 21st day after administration of the first cycle of AP regimen and the 8th day after the initiation of gefitinib treatment, she developed an acne-like rash, oral ulcer, and conjunctivitis, which later became blisters and ultimately denuded. The characteristic clinical courses were decisive for the diagnosis of TEN. Treatment with systemic steroids and immunoglobulin as well as supportive treatment led to an improvement of her general condition and a remarkable recovery.
Key wordsToxic epidermal necrolysis pemetrexed gefitinib non-small cell lung cancer drug-related bullous disease
Toxic epidermal necrolysis (TEN) is an acute life-threatening mucocutaneous disorder with an estimated incidence of 0.4–1.9/1,000,000 and a mortality higher than 20%–40% and is mostly drug-related (80%–95%) It is clinically characterized as a widespread sloughing of the skin and mucosa on both external and internal surfaces. Histologically, the denuded areas show full thickness epidermal necrosis.
Pemetrexed is a multitargeted antifolate drug approved for use in metastatic non-small cell lung cancer (NSCLC). AP regimen (pemetrexed plus cisplatin) is the preferred first-line chemotherapy for non-squamous NSCLC. The most common adverse events of pemetrexed include myelosuppression and gastrointestinal toxicity; cutaneous toxicity usually occurs as grades 1–2 rash. There also exist some severe cases that present acute generalized exanthematous pustulosis (AGEP), painful generalized erythematous patches, urticarial vasculitis[2–4], and TEN. To our knowledge, TEN related to pemetrexed has been described in only 4 other cases to date[5–8].
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) extensively used as the first-line treatment for EGFR-mutant metastatic NSCLC. The most common adverse effects include acne-like rash, diarrhea, and nausea, most of which are mild (grade 1/2) and reversible, and predominantly begin within the first treatment cycle. The acne-like rash (folliculitis) has been described variously as acne, rash, macropapular rash, pustular rash, vesiculobullous rash, or urticaria. Thus far, there have been no reports of TEN related to gefitinib toxicity.
Routine laboratory testing showed a white blood cell (WBC) count of 6.26 × 109/L [reference value: (3.69–9.16) × 109/L], neutrophil (NEU) proportion of 73.1% (reference: 50%–70%), and C-reactive protein (CRP) level of 16.36 mg/L (reference: 0–8.2 mg/L); both the Mycoplasma pneumoniae IgM antibody and Mac strains were negative. No suspicious fungus was found in the oral swab examination, nor did bacteria grow in the skin secretion culture.
Most TEN cases result from hypersensitive reaction to drugs, and sulfonamides, pyrazolones, barbiturates, and antiepileptics are the most frequent triggers. TEN usually occurs between 7 days to 8 weeks after drug administration. Upon readministration of the implicated drugs, it may develop within hours.
TEN is a T-cell-mediated disease with CD8+ T cells acting as the major mediator of keratinocyte death. Drug-induced CD8+ T-cell activation is highly specific for particular human leukocyte antigen (HLA) allotypes, placing certain populations at a greater risk of developing TEN. Granulysin is the main mediator of apoptosis, and soluble Fas ligand (sFasL), tumor necrosis factor-alpha (TNF-α), and granzyme B/perforin are important in the pathogenesis of TEN.
The diagnosis of TEN is made based on clinical and histological findings. Schwartz et al. put forward that the clinical features of TEN include (1) constitutional symptoms such as fever, malaise, anorexia, and pharyngitis; (2) erythematous, dusky, violaceous macules, morbilliform, or atypical targetoid macules starting on the trunk and spreading distally, confluence on the face, trunk, and elsewhere [the skin lesion area of TEN is greater than that of Stevens-Johnson syndrome (SJS)]; (3) manifests in flaccid bullae, epidermal sloughing, and necrosis with gray hue; (4) exfoliation of the epidermis involving 10% of body surface area for SJS, 10%–30% for SJS/TEN overlap, and >30% for TEN; (5) oral, genital, and ocular mucositis in nearly all patients; (6) tender skin and painful mucosal erosions; (7) positive Nikolsky sign; (8) positive Asboe-Hansen sign; (9) systemic symptoms always present in SJS/TEN overlap and TEN; and (10) respiratory tract epithelial involvement in 25% of patients with TEN. Histological features were described as follows: (1) full thickness epidermal necrosis; (2) subepidermal split, lymphocytic infiltrate at the dermoepidermal junction, CD4+ T cells in the dermis, and CD8+ T cells in the epidermis; and (3) endothelial apoptosis.
For mild and early stage TEN, the main differential diagnoses includes SJS, acute generalized exanthematous pustulosis (AGEP), erythema multiforme major (EMM), staphylococcal scalded skin syndrome (SSSS), drug-induced linear immunoglobulin A (IgA) dermatosis, acute graft versus host disease (GVHD), and a generalized morbilliform drug eruption, among other conditions[12,13]. Our patient’s clinical characteristics were consistent with the above criteria except items (8) and (10). Because the patient’s exfoliation was almost systemic, SJS and EMM were excluded; SSSS were excluded due to negative blood and rash cultures for bacteria and fungus as well as the presence of conjunctiva and oral mucosa damage. In addition, the patient’s rash mainly appeared as blisters and bullae due to erythema in the beginning stage, without pustules. Accordingly, AGEP and other diseases were also excluded.
Therefore, the patient was diagnosed with TEN according to typical clinical features. After treatment with glucocorticoids combined with immunoglobulin, her condition gradually improved, which verified the diagnosis of TEN. However, there also exists some deficiency in the diagnosis of this case, primarily the lack of mucocutaneous biopsy and immunologic examination to aid in the diagnosis.
There is currently no standardized treatment for TEN. An effective treatment requires early diagnosis, immediate discontinuation of the causative drugs, and supportive and specific treatment. Recently, the systematic application of glucocorticoids has been the major therapeutic regimen, and glucocorticoids combined with immunoglobulin can quickly control symptoms and shorten hospitalization time and is especially suitable for patients with concurrent infection.
Because this case of TEN occurred after AP and gefitinib sequential combination treatment, it is difficult to determine which drug was responsible for this toxicity. Thus far, there has been no report of TEN induced by cisplatin, whereas there has only been one case of SJS related to bleomycin-cisplatin combination treatment and another case of exfoliative dermatitis associated with cyclophosphamide-cisplatin combination treatment. To the best of our knowledge, 4 cases of TEN due to pemetrexed have been reported thus far: 1 due to pemetrexed alone, 1 related to pemetrexed plus carboplatin, and the other 2 related to pemetrexed plus cisplatin. The mucocutaneous disorder occurs between 2 days after the first cycle and 15 days after the second cycle of drug administration. Pemetrexed seems to be the most likely cause for our TEN case. Although our patient received gefitinib after AP chemotherapy, TEN occurred at the expected time and the patient did not develop mucocutaneous disorder after readministration of another EGFR-TKI, which supports pemetrexed as the initiator.
Although there is no report of EGFR-TKI-induced TEN thus far, gefitinib could not be ruled out for the cause of this case as EGFR-TKIs alter keratinocyte proliferation, differentiation, migration, and attachment, and cutaneous toxicity occurs in more than 50% of patients. Meanwhile, TEN occurring after 8 days of gefitinib administration has also increased the suspicion of gefitinib as the initiator. Another possible mechanism may be the synergistic effect on dermal toxicity for pemetrexed and gefitinib combination therapy. The basic skin toxicity of EGFR-TKIs may facilitate the occurrence of TEN induced by pemetrexed. Meanwhile, is there any possibility for the enhancement of EGFR-TKI-induced mucocutaneous disorder based on the alternation of folic acid metabolism of epithelial cells by pemetrexed? It is still unknown.
In summary, we report this case with the intent to further understand the potential rare mucocutaneous adverse effects of AP with gefitinib combination therapy. This case report also warns of the possibility of gefitinib as a potential initiator agent of TEN.
- Zany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet, 1999,353:2190–2194.View ArticleGoogle Scholar
- Bracke A, Van Marck E, Lambert J. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after reintroduction. Clin Exp Dermatol, 2009,34:337–339.View ArticlePubMedGoogle Scholar
- Vitiello M, Romanelli P, Kerdel FA. Painful generalized erythematous patches: a severe and unusual cutaneous reaction to pemetrexed. J Am Acad Dermatol, 2011,65:243–244.View ArticlePubMedGoogle Scholar
- Lopes G, Vincek V, Raez LE. Pemetrexed associated urticarial vasculitis. Lung Cancer J Iaslc, 2006,51:247–249.View ArticleGoogle Scholar
- Tummino C, Barlesi F, Tchouhadjian C, et al. Severe cutaneous toxicity after pemetrexed as a second line treatment for a refractory non small cell lung cancer. Rev Mal Respir, 2007,24:635–638.View ArticlePubMedGoogle Scholar
- Bosch-Barrera J, Gaztanaga M, Ceballos J, et al. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. Onkologie, 2009,32:580–584.View ArticlePubMedGoogle Scholar
- Scheinpflug K, Menzel C, Koch A, et al. Toxic epidermal necrolysis related to cisplatin and pemetrexed for metastatic non-small cell lung cancer. Onkologie, 2012,35:600–603.View ArticlePubMedGoogle Scholar
- Then C, von Einem JC, Müller D, et al. Toxic epidermal necrolysis after pemetrexed and cisplatin for non-small cell lung cancer in a patient with sharp syndrome. Onkologie, 2012,35:783–786.View ArticlePubMedGoogle Scholar
- Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis, 2010,5:39.PubMed CentralView ArticlePubMedGoogle Scholar
- Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol, 2013,69:173.e1–173.e13.Google Scholar
- Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol, 2013,69:187.e1–187.e16.View ArticleGoogle Scholar
- Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol, 2012,51:889–902.View ArticlePubMedGoogle Scholar
- Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol, 2007,56:181–200.View ArticlePubMedGoogle Scholar
- Brodsky A, Aparici I, Argeri C, et al. Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity. J Clin Pharmacol, 1989,29:821–823.View ArticlePubMedGoogle Scholar
- Lee TC, Hook CC, Long HJ. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin Proc, 1994,69:80–82.View ArticlePubMedGoogle Scholar